Accessibility setting


Select language

Skip to secondary menu

Skip to content

Jehovah’s Witnesses


Perioperative Care

Management and Optimization of Hemostasis

Recent advances in the development of specific antidotes for target-specific oral anticoagulants.

Mo Y, Yam FK.

Source‎: Pharmacotherapy 2015;35(2):198-207.

Indexed‎: PubMed 25644580

DOI‎: 10.1002/phar.1532

First-line therapy with coagulation factor concentrates combined with point-of-care coagulation testing is associated with decreased allogeneic blood transfusion in cardiovascular surgery: a retrospective, single-center cohort study.

Görlinger K, Dirkmann D, Hanke AA, Kamler M, Kottenberg E, Thielmann M, Jakob H, Peters J.

Source‎: Anesthesiology 2011;115(6):1179-1191.

Indexed‎: PubMed 21970887

DOI‎: 10.1097/ALN.0b013e31823497dd

Consensus recommendations for the off-label use of recombinant human factor VIIa (NovoSeven(R)) therapy.

Shander A, Goodnough LT, Ratco T, Matuszewski KA, Cohn S, Diringer M, Edmunds H, Lawson J, MacLaren R, Ness P, Shere-Wolfe R, Dubois R.

Source‎: Pharm Ther 2005;30(11):644-58.

Indexed‎: Embase 2005576568

Bloodless orthotopic heart transplantation in a Jehovah's Witness.

Dallas T, Welsby I, Bottiger B, Milano C, Daneshmand M, Guinn N.

Source‎: A A Case Rep 2015;4(10):140-2.

Indexed‎: PubMed 25974419

DOI‎: 10.1213/XAA.0000000000000067

Romiplostim treatment allows for platelet transfusion-free liver transplantation in pediatric thrombocytopenic patient with primary sclerosing cholangitis.

Minowa K, Arai K, Kasahara M, Sakamoto S, Shimizu H, Nakano N, Ito R, Obayashi N, Nakazawa A, Ishiguro A.

Source‎: Pediatr Transplant 2014;18(6):E212-5.

Indexed‎: PubMed 25041553

DOI‎: 10.1111/petr.12308

Fibrinogen as a therapeutic target for bleeding: a review of critical levels and replacement therapy.

Levy JH, Welsby I, Goodnough LT.

Source‎: Transfusion 2014;54(5):1389-405; quiz 1388.

Indexed‎: PubMed 24117955

DOI‎: 10.1111/trf.12431

Systematic review, meta-analysis and meta-regression of the effect of tranexamic acid on surgical blood loss.

Ker K, Prieto-Merino D, Roberts I.

Source‎: Br J Surg 2013;100(10):1271-9.

Indexed‎: PubMed 23839785

DOI‎: 10.1002/bjs.9193

Management of severe perioperative bleeding: Guidelines from the European Society of Anaesthesiology.

Kozek-Langenecker SA, Afshari A, Albaladejo P, Santullano CA, De Robertis E, Filipescu DC, Fries D, Görlinger K, Haas T, Imberger G, Jacob M, Lancé M, Llau J, Mallett S, Meier J, Rahe-Meyer N, Samama CM, Smith A, Solomon C, Van der Linden P, Wikkelsø AJ, Wouters P, Wyffels P.

Source‎: Eur J Anaesthesiol 2013;30(6):270-382.

Indexed‎: PubMed 23656742

DOI‎: 10.1097/EJA.0b013e32835f4d5b

Effects of fibrinogen concentrate as first-line therapy during major aortic replacement surgery: a randomized, placebo-controlled trial.

Rahe-Meyer N, Solomon C, Hanke A, Schmidt DS, Knoerzer D, Hochleitner G, Sørensen B, Hagl C, Pichlmaier M.

Source‎: Anesthesiology 2013;118(1):40-50.

Indexed‎: PubMed 23249928

DOI‎: 10.1097/ALN.0b013e3182715d4d

Eltrombopag before procedures in patients with cirrhosis and thrombocytopenia.

Afdhal NH, Giannini EG, Tayyab G, Mohsin A, Lee JW, Andriulli A, Jeffers L, McHutchison J, Chen PJ, Han KH, Campbell F, Hyde D, Brainsky A, Theodore D; ELEVATE Study Group.

Source‎: N Engl J Med 2012;367(8):716-24.

Indexed‎: PubMed 22913681

DOI‎: 10.1056/NEJMoa1110709

Putting the record straight on aprotinin as safe and effective: results from a mixed treatment meta-analysis of trials of aprotinin.

Howell N, Senanayake E, Freemantle N, Pagano D.

Source‎: J Thorac Cardiovasc Surg 2013;145(1):234-40.

Indexed‎: PubMed 22889481

DOI‎: 10.1016/j.jtcvs.2012.07.018

Preoperative use of romiplostim in thrombocytopenic patients with chronic hepatitis C and liver cirrhosis.

Moussa MM, Mowafy N.

Source‎: J Gastroenterol Hepatol 2013;28(2):335-41.

Indexed‎: PubMed 22849409

DOI‎: 10.1111/j.1440-1746.2012.07246.x

Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.

Ker K, Edwards P, Perel P, Shakur H, Roberts I.

Source‎: BMJ 2012;344:e3054.

Indexed‎: PubMed 22611164

DOI‎: 10.1136/bmj.e3054

Recombinant factor VIIa as last-resort treatment of desperate haemorrhage.

Palmason R, Vidarsson B, Sigvaldason K, Ingimarsson JP, Gudbjartsson T, Sigurdsson GH, Onundarson PT.

Source‎: Acta Anaesthesiol Scand 2012;56(5):636-44.

Indexed‎: PubMed 22489992

DOI‎: 10.1111/j.1399-6576.2012.02688.x

Bleeding in a Jehovah's Witness patient undergoing a redo aortic valve replacement controlled with cryoprecipitate and a prothrombin complex concentrate.

Robblee JA, Wilkes PR, Dickie SJ, Rubens FD, Bormanis J.

Source‎: Can J Anaesth 2012;59(3):299-303.

Indexed‎: PubMed 22161243

DOI‎: 10.1007/s12630-011-9647-7

The medical section of is designed as an informational resource primarily for use by clinicians and other health-care professionals. It provides neither medical advice nor treatment recommendations and does not substitute for an appropriately qualified health-care provider. The clinical literature cited is not published by Jehovah’s Witnesses, but it outlines transfusion-alternative strategies that might be considered. It is the responsibility of each qualified health-care provider to maintain awareness of new information, discuss options for care, and assist patients in making choices in accord with their medical condition, wishes, values, and beliefs. Not all listed strategies are appropriate or acceptable to all patients.

Patients: Always seek the advice of your doctor or other qualified health-care provider regarding medical conditions or treatments. Check with a doctor if you suspect you are ill.

The use of this website is governed by its terms of use.